- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01556308
Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara
Introduction: Epidermolysis Bullosa Simplex-Dowling-Meara (DM-EBS) is a rare genodermatosis characterized by spontaneous or post traumatic large cutaneous blisters. No curative treatment is actually available. Some data suggest a role of inflammation in the occurrence of blisters. The aim of this study is to study the epidermis inflammatory mechanisms in DM-EBS.
Material and methods: A first retrospective immunohistochemical study will be led on remainder skin biopsies of DM-EBS patients took for the diagnosis. A second clinical multicentric prospective study will be led on 8 patients older than 1 year with severe DM-EBS. After informed written consent, they will answer to a standardized questionnaire. In case of flare of the disease, the liquid and the top of the blisters will be took. Samples will be analyzed in the Pr Nicolas 851 INSERM unit. After centrifugation of the liquid blisters, the repartition of inflammatory cells will be evaluated by Fluorescence Activated Cell Sorting on the pellet. Markers of inflammation will be evaluated on the surnageant with Luminex® technical with a multiplex targeting cytokines and chemokines. An immuno-histochemic analysis in association with a quantitative PCR will be made on the top of the blisters. If unknown, genotypic study will be made.
Perspectives: A better comprehension of physiopathological mechanisms in DM-EBS could offer new therapeutic ways.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nice, France, 06200
- Hôpital Archet 2
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male or female
- older than 1 year-old
- severe Dowling Meara epidermolysis bullosa (more than 2 blisters per day)
- systematic written informed consent
- child consent
- affiliated to french social security
Exclusion Criteria:
- younger than one year-old
- no consent
- non affiliated to french social security
- participation to another clinical trial within 3 months ago
- intercurrent disease justifying the withdrawal of the study
- own patient decision to stop the study, withdrawal of informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DM-EBS
|
the liquid and the top of blisters will be took.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Markers of inflammation in epidermis in patients with severe DM-BS
Time Frame: Baseline
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
clinical characterization of DM-EBS Genotype-phenoty
Time Frame: Baseline
|
Baseline
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-AOI-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epidermolysis Bullosa Simplex Dowling Meara
-
Castle Creek Pharmaceuticals, LLCCompletedDystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Simplex | Junctional Epidermolysis Bullosa | Epidermolysis Bullosa (EB)United States
-
TWi Biotechnology, Inc.RecruitingGeneralized Epidermolysis Bullosa SimplexTaiwan, Australia, Philippines
-
Joyce TengRecruitingHealthy | Epidermolysis Bullosa | Genetic Skin Disease | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, JunctionalUnited States
-
InMed Pharmaceuticals Inc.CompletedEpidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, Junctional | Kindler SyndromeFrance, Germany, Greece, Israel, Italy
-
ProgenaBiomeRecruitingEpidermolysis Bullosa | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa SimplexUnited States
-
Castle Creek Pharmaceuticals, LLCCompletedEpidermolysis Bullosa | Epidermolysis Bullosa SimplexUnited States
-
Centre Hospitalier Universitaire de NiceUnknownEpidermolysis BullosaFrance
-
Castle Creek Pharmaceuticals, LLCTerminatedEpidermolysis Bullosa SimplexUnited States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
-
Tel-Aviv Sourasky Medical CenterUnknownEpidermolysis Bullosa Simplex
-
National Medical Research Center for Children's...Active, not recruitingEpidermolysis Bullosa | Hormone Disturbance | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Dermatologic Disease | Epidermolysis Bullosa, Junctional | Puberty Disorders | Kindler SyndromeRussian Federation
Clinical Trials on Taking of liquid and top of blisters
-
The Cleveland ClinicThe Huron FoundationCompletedMedication Adherence | Medication Compliance
-
University Hospital, MontpellierTerminated
-
Assistance Publique Hopitaux De MarseilleCompletedProstate Cancer | Benign Prostatic HypertrophyFrance
-
Boston CollegeNational Institute on Aging (NIA)CompletedHeart FailureUnited States
-
Quanta MedicalCompletedConstipation - FunctionalFrance
-
Medical University InnsbruckCompletedBlood Clotting | Blood Platelet TransfusionAustria, Denmark
-
University Hospital, Strasbourg, FranceRecruitingElectronic CigaretteFrance
-
Leiden University Medical CenterNot yet recruitingColorectal Cancer | Image | Liver Metastasis Colon Cancer
-
Seoul National University Bundang HospitalRecruitingPain, Postoperative | Analgesia | Artificial Intelligence | Facial ExpressionKorea, Republic of